


# **Prolonged Drug Use Changes the Brain In Fundamental and Long-Lasting Ways**

**Voluntary  
Drug Use**



**Compulsive  
Drug Use  
(Addiction)**



# Rumor-based policy?

A major demand that competes for scarce community resources are for the treatment needs of those who have become addicted to methamphetamine (MA).

# Rumor based policy?

Critical questions facing policy makers and public health officials in areas with burgeoning MA use:

- How many people need treatment?
- What kind of treatment works for MA abuse/dependence?
- How much treatment is needed to successfully help MA users?

# Rumor based policy?

A pervasive rumor has surfaced in many geographic areas with elevated MA problems:

- ✓ MA users are virtually untreatable with negligible recovery rates.
- ✓ Rates from 5% to less than 1% have been quoted in newspaper articles and reported in conferences.

**\*\*The resulting conclusion is that spending money on treating MA users is futile and wasteful, BUT no data exists that supports these statistics\*\***

# Statistics

During the 2002-2003 fiscal year:

- 35,947 individuals were admitted to treatment in California under the Substance Abuse and Crime Prevention Act funding.
- Of this group, 53% reported MA as their primary drug problem

# Statistics

Analysis of:

- Drop out rates
- Retention in treatment rates
- Re-incarceration rates
- Other measures of outcome

All these measures indicate that MA users respond in an equivalent manner as individuals admitted for other drug abuse problems.

# Does treatment work?

- Treatment programs and personnel are unprepared for the influx of MA users.
- Although some traditional elements may be appropriate, many staff report feeling unprepared to address many of the clinical challenges presented by these patients.



# Clinical Challenges

- Poor treatment engagement rates
- High drop out rates
- Severe paranoia
- High relapse rates
- Ongoing episodes of psychosis
- Severe craving
- Protracted dysphoria
- Anhedonia

# Treatment Options

# CSAT Tip #33

- A useful resource that presents a review of the existing knowledge about treatment effectiveness with stimulant users.
- The following issues should be addressed by the clinical staff:
  - Meth and sexual behavior
  - Meth and weight gain
  - Meth and ongoing paranoia

# Medications

- Currently, there are NO medications that can quickly and safely **reverse** life threatening MA overdose.
- There are NO medications that can reliably **reduce** paranoia and psychotic symptoms, that contribute to episodes of dangerous and violent behavior associated with MA use.

# Psychosocial/Behavioral Treatments

- NIDA has also produced several manuals that have been empirically tested with stimulant-using populations, including:
  - Cognitive Behavioral Therapy (CBT)
  - Contingency Management (CM)


# Psychosocial/Behavioral

- Materials were tested with cocaine and crack users, but there is evidence that cocaine and MA users respond similarly to behavioral and cognitive strategies.
- Both CBT and CM produce substantial reduction of cocaine and virtually identical reduction in MA.
- Treatments with evidence of efficacy for treating cocaine appear to be equally effective with MA users.

# Contingency Management


- Preliminary finding appear very positive.
- Powerful tool to improve engagement and retention and to reduce MA use

## Mean weeks of consecutive abstinence





# Methamphetamine Outcomes from CTN 006



# Matrix Model

- Is a manualized, 16-week, non-residential, psychosocial approach used for the treatment of drug dependence.
- Designed to integrate several interventions into a comprehensive approach. Elements include:
  - Individual counseling
  - Cognitive behavioral therapy
  - Motivational interviewing
  - Family education groups
  - Urine testing
  - Participation in 12-step programs

# Matrix Model of Outpatient Treatment

## *Organizing Principles of Matrix Treatment*

- Program components based upon scientific literature on promotion of behavior change.
- Program elements and schedule selected based on empirical support in literature and application.
- Program focus is on current behavior change in the present and not underlying “causes” or presumed “psychopathology”.
- Matrix “treatment” is a process of “coaching”, educating, supporting and reinforcing positive behavior change.

# Matrix Model of Outpatient Treatment

## *Organizing Principles of Matrix Treatment*

- Non-judgemental, non-confrontational relationship between therapist and patient creates positive bond which promotes program participation.
- Therapist as a “coach”
- Positive reinforcement used extensively to promote treatment engagement and retention.
- Verbal praise, group support and encouragement other incentives and reinforcers.

# Matrix Model of Outpatient Treatment

## *Organizing Principles of Matrix Treatment*

- Accurate, understandable, scientific information used to educate patient and family members
  - Effects of drugs and alcohol
  - Addiction as a “brain disease”
  - Critical issues in “recovering” from addiction

# Matrix Model of Outpatient Treatment

## *Organizing Principles of Matrix Treatment*

- Behavioral strategies used to promote cessation of drug use and behavior change
  - Scheduling time to create “structure”
  - Educating and reinforcing abstinence from all drugs and alcohol
  - Promoting and reinforcing participation in non-drug-related activities

# Matrix Model of Outpatient Treatment

## *Organizing Principles of Matrix Treatment*

- Cognitive-Behavioral strategies used to promote cessation of drug use and prevention of relapse.
  - Teaching the avoidance of “high risk” situations
  - Educating about “triggers” and “craving”
  - Training in “thought stopping” technique
  - Teaching about the “abstinence violation effect”
  - Reinforcing application of principles with verbal praise by therapist and peers

# Matrix Model of Outpatient Treatment

## *Organizing Principles of Matrix Treatment*

- Involvement of family members to support recovery.
- Encourage participation in self-help meetings
- Urine testing to monitor drug use and reinforce abstinence
- Social support activities to maintain abstinence



# The Matrix Model

<i>Monday</i>	<i>Wednesday</i>	<i>Friday</i>
<b>Early Recovery Skills</b>  <b>Weeks 1-4</b>	<b>Family/education</b>  <b>Weeks 1-12</b>	<b>Early Recovery Skills</b>  <b>Weeks 1-4</b>
<b>Relapse Prevention</b>  <b>Weeks 1-16</b>	<b>Social Support</b>  <b>Weeks 13-16</b>	<b>Relapse Prevention</b>  <b>Weeks 1-16</b>

- ❖ Urine or breath alcohol tests once per week, weeks 1-16

# Project Structure:

## **Study Sites**

Billings, MT

Honolulu, HI

San Mateo, CA (2)

San Diego, CA

Concord, CA

Costa Mesa, CA

Hayward, CA

## **Coordinating Center**

UCLA Integrated Substance Abuse Programs

## **Steering Committee**


## **Scientific Advisory Board**

## **Community Advisory Board**


# Baseline Demographics

Participants Served (n)	1016
Age (mean)	32.8 years
Education (mean)	12.2 years
Methamphetamine Use (mean)	7.5 years
Marijuana Use (mean)	7.2 years
Alcohol Use (mean)	7.6 years


# Gender Distribution of Participants




# Ethnic Identification of Participants




# Route of Methamphetamine Administration





# Changes from Baseline to Treatment-end


# Days of Methamphetamine Use in Past 30 (ASI)



Possible is 0-30;  $t_{\text{paired}}=20.90$ ;  $p\text{-value}<0.000$  (highly sig.)




# Beck Depression Inventory (BDI) Total Scores



Possible is 0-63;  $t_{\text{paired}}=16.87$ ;  $p\text{-value}<0.000$  (highly sig.)

# Positive Symptom Total (PST) from Brief Symptom Inventory (BSI)



Possible is 0-53;  $t_{\text{paired}}=14.33$ ;  $p\text{-value}<0.000$  (highly sig.)

# Mean Number of Weeks in Treatment



# Mean Number of UA's that were MA-free during treatment



Figure 4. Percent completing treatment, by group

	Matrix 16	TAU
Completer	40.85	34.16
Not Completer	59.15	65.84

$\chi^2=4.68, p=0.031$

**Figure 6. Participant self-report of MA use (number of days during the past 30) at enrollment, discharge, and 6-month follow-up, by treatment condition**

